A multicentre randomised trial of short neoadjuvant chemotherapy (VAPEC-B) plus involved field radiotherapy (MIT) versus mantle radiotherapy

Submission date	Recruitment status No longer recruiting Overall study status	Prospectively registered		
01/07/2001		☐ Protocol		
Registration date		Statistical analysis plan		
01/07/2001	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
17/02/2015	Cancer			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)Scientific

Contact name

- -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number NCT00002987

Secondary identifying numbers

LY07

Study information

Scientific Title

A multicentre randomised trial of short neo-adjuvant chemotherapy (VAPEC-B) plus involved field radiotherapy (MIT) versus mantle radiotherapy

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Lung (non-small cell) cancer

Interventions

- 1. VAPEC-B regimen: minimal initial chemotherapy therapy involving vincristine, adriamycin, etoposide, cyclophosphamide and bleomycin, followed by involved field radiotherapy
- 2. Control regimen: mantle radiotherapy

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Vincristine, adriamycin, etoposide, cyclophosphamide and bleomycin

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1995

Completion date

26/06/2001

Eligibility

Key inclusion criteria

- 1. Patients aged between 16 and 75 years
- 2. Histologically proven Hodgkin's disease, stage IA or IIA with no mediastinal bulk
- 3. No previous treatment
- 4. No previous malignancy other than basal cell carcinoma or cervical intra-epithelial neoplasms
- 5. No concurrent illness which would contraindicate chemotherapy or radiotherapy
- 6. Not documented evidence of Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

Not provided at time of registration

Key exclusion criteria

If Hodgkin's disease is below the diaphragm only, patients are not eligible for this trial

Date of first enrolment

01/01/1995

Date of final enrolment

26/06/2001

Locations

Countries of recruitment

United Kingdom

Study participating centre

.

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123 Lincoln's Inn Fields London United Kingdom WC2A 3PX +44 (0)207 317 5186 kate.law@cancer.org.uk

Sponsor type

Charity

Website

http://www.cancer.org.uk

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Abstract results	abstract A-E08, 39	07/09/2004		No	No